Publications by PCC-funded Researchers

Recently Chocair et al published an article in BMC Cancer on research that was funded by a Prostate Cancer Canada Pilot Grant. We’ve provided a synopsis of the results below.

This study showed that prostate tumors without PTEN, a tumor suppressor gene, were associated with a higher risk of cancer recurrence – thus, PTEN loss may indicate which tumours are aggressive. The study also showed that the loss of PTEN was associated with a decrease in androgen receptor (AR), a key protein in the progression of prostate cancer. This may have consequences on cancer response to the commonly used androgen ablation therapy. These findings will be studied in a larger group of patients to fully evaluate the impact of the results. This research is a step toward the development of personalized treatment for prostate cancer based on the molecular characteristics of the tumors.

Full article citation:
PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity

Khalil Choucair, Joshua Ejdelman, Fadi Brimo, Armen Aprikian, Simone Chevalier and Jacques Lapointe  
BMC Cancer 2012, 12:543,Published: 22 November 2012 

Dr. John Lewis, a PCC-funded researcher, recently published an article describing breakthroughs in prostate cancer research using nanotechnology. Here’s a snapshot of these recent advances:
Chemotherapies for prostate and other cancers can result in serious side effects. This is because the amount of drug that ends up in the tumour is usually less than 10% of the drug that accumulates in normal tissues. In an article published in the journal Nano Letters, Dr. Lewis and his collaborators describe a new technology that enables the creation of "smart" nanoparticles that seek out cancer cells while avoiding healthy tissues. Prostate Cancer Canada, through its Pilot Grant Program, is supporting Dr. Lewis's group as they use this new technology to test an exciting new "smart" nanoparticle that targets the tumour's blood supply. These nanoparticles should allow us to light up those prostate tumours that are most likely to be lethal, and to deliver chemotherapies directly to the cancer. 

Article Citation:
Discovery of Novel Integrin Ligands from Combinatorial Libraries Using a Multiplex “Beads on a Bead” Approach

Choi-Fong Cho, Giulio A. Amadei, Daniel Breadner, Leonard G. Luyt, and John D. Lewis 

Nano Lett., 2012, 12 (11), pp 5957–5965

Inscrivez-vous à nos nouvelles

* obligatoire

Contenu en vedette
Rocco Rossi conclut un mandat réussi de cinq ans à titre de président et chef de la direction de Cancer de la Prostate Canada

7 septembre 2017 - TORONTO (ONTARIO) - C’est avec beaucoup d’émotion que le président et chef de la direction de longue date de Cancer de la Prostate Canada (CPC), Rocco Rossi, a officiellement annoncé aujourd’hui qu’il quittera ses fonctions à la barre de l’organisation le 31 décembre 2017.

La Fondation Movember et Cancer de la Prostate Canada font équipe pour transformer la recherche en résultats

26 juillet 2017 – TORONTO (ONTARIO) – Fidèles à leur longue tradition de partenariat pour le financement de recherches de grande qualité sur le cancer de la prostate au Canada, Cancer de la Prostate Canada (CPC) et la Fondation Movember ont annoncé aujourd’hui deux nouveaux projets qui offrent un potentiel très réel de changer concrètement le cours des choses pour les hommes atteints de formes virulentes du cancer de la prostate.

Cancer de la prostate nouvelles